This article only represents the author's own views.
After bleeding red ink for years, one of China’s leading makers of next-generation cancer drugs may be approaching a financial turning point.
Armed with a blockbuster drug, BeiGene Ltd. (688235.SH; 6160.HK; ONC.US) has served notice that it expects its operating results to land in the black this year, when the company’s revenue is projected to exceed research and business costs.
您已阅读8%（432字），剩余92%（4672字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。